JP2011507854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507854A5 JP2011507854A5 JP2010539504A JP2010539504A JP2011507854A5 JP 2011507854 A5 JP2011507854 A5 JP 2011507854A5 JP 2010539504 A JP2010539504 A JP 2010539504A JP 2010539504 A JP2010539504 A JP 2010539504A JP 2011507854 A5 JP2011507854 A5 JP 2011507854A5
- Authority
- JP
- Japan
- Prior art keywords
- imidazo
- pyridin
- pyridazin
- acetamide
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 57
- 150000001875 compounds Chemical class 0.000 claims description 39
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 39
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 37
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 37
- 125000001072 heteroaryl group Chemical group 0.000 claims description 37
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000003107 substituted aryl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- -1 compound salt Chemical class 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims 24
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 12
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- YMDAQEULQVMMAG-UHFFFAOYSA-N n-[6-[6-chloro-5-[[4-[1-(methylamino)ethyl]phenyl]sulfonylamino]pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC(C(C)NC)=CC=C1S(=O)(=O)NC1=CC(C2=NN3C=C(NC(C)=O)N=C3C=C2)=CN=C1Cl YMDAQEULQVMMAG-UHFFFAOYSA-N 0.000 claims 3
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- KAGJYOMRCXMENF-UHFFFAOYSA-N 1-[6-(6-cyano-5-propan-2-yloxypyridin-3-yl)imidazo[1,2-b]pyridazin-2-yl]-3-(2-piperidin-1-ylethyl)urea Chemical compound N1=C(C#N)C(OC(C)C)=CC(C2=NN3C=C(NC(=O)NCCN4CCCCC4)N=C3C=C2)=C1 KAGJYOMRCXMENF-UHFFFAOYSA-N 0.000 claims 1
- BHHWPAVCSWIDJO-UHFFFAOYSA-N 1-[6-[6-chloro-5-(dimethylamino)pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]-3-(2-piperidin-1-ylethyl)urea Chemical compound N1=C(Cl)C(N(C)C)=CC(C2=NN3C=C(NC(=O)NCCN4CCCCC4)N=C3C=C2)=C1 BHHWPAVCSWIDJO-UHFFFAOYSA-N 0.000 claims 1
- JZPZVXLZIFSSDS-UHFFFAOYSA-N 5-[2-amino-6-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]imidazo[1,2-b]pyridazin-3-yl]-2-fluorobenzoic acid Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C2=NN3C(C=4C=C(C(F)=CC=4)C(O)=O)=C(N)N=C3C=C2)=C1 JZPZVXLZIFSSDS-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 239000000677 immunologic agent Substances 0.000 claims 1
- 229940124541 immunological agent Drugs 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- ZYLGQXHDBGCALW-UHFFFAOYSA-N n-[5-(2-amino-3-pyridin-2-ylbenzimidazol-5-yl)-2-chloropyridin-3-yl]-4-fluorobenzenesulfonamide Chemical compound NC1=NC2=CC=C(C=3C=C(NS(=O)(=O)C=4C=CC(F)=CC=4)C(Cl)=NC=3)C=C2N1C1=CC=CC=N1 ZYLGQXHDBGCALW-UHFFFAOYSA-N 0.000 claims 1
- LENBBFNKOZJFQK-UHFFFAOYSA-N n-[5-(2-amino-3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-yl)-2-chloropyridin-3-yl]methanesulfonamide Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C2=NN3C(C=4C=CN=CC=4)=C(N)N=C3C=C2)=C1 LENBBFNKOZJFQK-UHFFFAOYSA-N 0.000 claims 1
- ABCZKUIDXGHMIH-UHFFFAOYSA-N n-[5-(2-aminoimidazo[1,2-a]pyridin-6-yl)-2-chloropyridin-3-yl]-4-fluorobenzenesulfonamide Chemical compound C1=CC2=NC(N)=CN2C=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 ABCZKUIDXGHMIH-UHFFFAOYSA-N 0.000 claims 1
- FPJNXVCSICMXRJ-UHFFFAOYSA-N n-[5-(2-aminoimidazo[1,2-b]pyridazin-6-yl)-2-chloropyridin-3-yl]-4-fluorobenzenesulfonamide Chemical compound C1=CC2=NC(N)=CN2N=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 FPJNXVCSICMXRJ-UHFFFAOYSA-N 0.000 claims 1
- CTRIVXOXDTZPIE-UHFFFAOYSA-N n-[5-(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)pyridin-3-yl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=1)=CN=CC=1C(N1N=2)=NN=C1C=CC=2C1=CC=CC=C1 CTRIVXOXDTZPIE-UHFFFAOYSA-N 0.000 claims 1
- GOCCRGWDVWVMNU-UHFFFAOYSA-N n-[5-[2-amino-3-(2-methylpyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl]-2-chloropyridin-3-yl]-3-(difluoromethoxy)benzenesulfonamide Chemical compound C1=NC(C)=CC(C=2N3N=C(C=CC3=NC=2N)C=2C=C(NS(=O)(=O)C=3C=C(OC(F)F)C=CC=3)C(Cl)=NC=2)=C1 GOCCRGWDVWVMNU-UHFFFAOYSA-N 0.000 claims 1
- UEFWWWBAPHUGMF-UHFFFAOYSA-N n-[5-[2-amino-3-(3-fluorophenyl)imidazo[1,2-b]pyridazin-6-yl]-2-chloropyridin-3-yl]methanesulfonamide Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C2=NN3C(C=4C=C(F)C=CC=4)=C(N)N=C3C=C2)=C1 UEFWWWBAPHUGMF-UHFFFAOYSA-N 0.000 claims 1
- VTQHLGNTFCRBJH-UHFFFAOYSA-N n-[6-(2-fluoropyridin-4-yl)imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C1=CC=NC(F)=C1 VTQHLGNTFCRBJH-UHFFFAOYSA-N 0.000 claims 1
- GVQACZSEGZYBKO-UHFFFAOYSA-N n-[6-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN2C=C(NC(C)=O)N=C2C=C1 GVQACZSEGZYBKO-UHFFFAOYSA-N 0.000 claims 1
- LEXVFSSQSRHCDF-UHFFFAOYSA-N n-[6-(3-methylsulfanylphenyl)imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CSC1=CC=CC(C2=NN3C=C(NC(C)=O)N=C3C=C2)=C1 LEXVFSSQSRHCDF-UHFFFAOYSA-N 0.000 claims 1
- XWJGCEJHQFOLQE-UHFFFAOYSA-N n-[6-(5,6-dimethoxypyridin-3-yl)imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound N1=C(OC)C(OC)=CC(C2=NN3C=C(NC(C)=O)N=C3C=C2)=C1 XWJGCEJHQFOLQE-UHFFFAOYSA-N 0.000 claims 1
- WPDUKUOHEYEXSQ-UHFFFAOYSA-N n-[6-(5-methylsulfanylpyridin-3-yl)imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CSC1=CN=CC(C2=NN3C=C(NC(C)=O)N=C3C=C2)=C1 WPDUKUOHEYEXSQ-UHFFFAOYSA-N 0.000 claims 1
- QJCLRSIPLYBASE-UHFFFAOYSA-N n-[6-(5-methylsulfonylpyridin-3-yl)imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C1=CN=CC(S(C)(=O)=O)=C1 QJCLRSIPLYBASE-UHFFFAOYSA-N 0.000 claims 1
- MVJUDIWGLAFUEU-UHFFFAOYSA-N n-[6-[2-(2-fluorophenyl)sulfanylpyridin-4-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CC=NC=1SC1=CC=CC=C1F MVJUDIWGLAFUEU-UHFFFAOYSA-N 0.000 claims 1
- TXKYOSTZYAABSD-UHFFFAOYSA-N n-[6-[3-(isoquinolin-5-ylsulfonylamino)phenyl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound N1=CC=C2C(S(=O)(=O)NC=3C=CC=C(C=3)C3=NN4C=C(N=C4C=C3)NC(=O)C)=CC=CC2=C1 TXKYOSTZYAABSD-UHFFFAOYSA-N 0.000 claims 1
- VDCDQHDSIGFSEK-UHFFFAOYSA-N n-[6-[3-(naphthalen-1-ylsulfonylamino)phenyl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC=C2C(S(=O)(=O)NC=3C=CC=C(C=3)C3=NN4C=C(N=C4C=C3)NC(=O)C)=CC=CC2=C1 VDCDQHDSIGFSEK-UHFFFAOYSA-N 0.000 claims 1
- WQJAPCZXLCHGEO-UHFFFAOYSA-N n-[6-[3-[(4-methylphenyl)sulfonylamino]phenyl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CC=CC=1NS(=O)(=O)C1=CC=C(C)C=C1 WQJAPCZXLCHGEO-UHFFFAOYSA-N 0.000 claims 1
- QZXWQIUHLLWMMU-UHFFFAOYSA-N n-[6-[3-[methyl-(4-methylphenyl)sulfonylamino]phenyl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C=1C=CC(C2=NN3C=C(NC(C)=O)N=C3C=C2)=CC=1N(C)S(=O)(=O)C1=CC=C(C)C=C1 QZXWQIUHLLWMMU-UHFFFAOYSA-N 0.000 claims 1
- OBOFGDDXBXEDIK-UHFFFAOYSA-N n-[6-[5-(dimethylamino)-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CN(C)C1=CC(C2=NN3C=C(NC(C)=O)N=C3C=C2)=CN=C1OCCN1CCOCC1 OBOFGDDXBXEDIK-UHFFFAOYSA-N 0.000 claims 1
- CWCUFSAPQCMYEG-UHFFFAOYSA-N n-[6-[5-(dimethylamino)-6-(2-morpholin-4-ylethylamino)pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CN(C)C1=CC(C2=NN3C=C(NC(C)=O)N=C3C=C2)=CN=C1NCCN1CCOCC1 CWCUFSAPQCMYEG-UHFFFAOYSA-N 0.000 claims 1
- JDLFNYFQVDBZGX-UHFFFAOYSA-N n-[6-[5-(propan-2-ylamino)-6-(trifluoromethyl)pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound N1=C(C(F)(F)F)C(NC(C)C)=CC(C2=NN3C=C(NC(C)=O)N=C3C=C2)=C1 JDLFNYFQVDBZGX-UHFFFAOYSA-N 0.000 claims 1
- PMLPEKOZYDGQFG-UHFFFAOYSA-N n-[6-[5-[(4-methylphenyl)sulfonylamino]pyridin-3-yl]imidazo[1,2-a]pyrazin-2-yl]acetamide Chemical compound N1=CC2=NC(NC(=O)C)=CN2C=C1C(C=1)=CN=CC=1NS(=O)(=O)C1=CC=C(C)C=C1 PMLPEKOZYDGQFG-UHFFFAOYSA-N 0.000 claims 1
- GBQNMMOBKMRTOR-UHFFFAOYSA-N n-[6-[5-[(4-tert-butylphenyl)sulfonylamino]-6-chloropyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GBQNMMOBKMRTOR-UHFFFAOYSA-N 0.000 claims 1
- BLJRCNSXJLQTSS-UHFFFAOYSA-N n-[6-[5-[(4-tert-butylphenyl)sulfonylamino]-6-cyanopyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(C#N)C=1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 BLJRCNSXJLQTSS-UHFFFAOYSA-N 0.000 claims 1
- KBFJYZWCROOHAH-UHFFFAOYSA-N n-[6-[5-[(4-tert-butylphenyl)sulfonylamino]-6-ethynylpyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(C#C)C=1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 KBFJYZWCROOHAH-UHFFFAOYSA-N 0.000 claims 1
- QDHDUMVPCAHHSF-UHFFFAOYSA-N n-[6-[6-(2-morpholin-4-ylethylamino)-5-(propan-2-ylamino)pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CC(C)NC1=CC(C2=NN3C=C(NC(C)=O)N=C3C=C2)=CN=C1NCCN1CCOCC1 QDHDUMVPCAHHSF-UHFFFAOYSA-N 0.000 claims 1
- UHQWQCNMMZGHRC-UHFFFAOYSA-N n-[6-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-3-(3-fluorophenyl)imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CC(=O)NC=1N=C2C=CC(C=3C=C(NS(C)(=O)=O)C(Cl)=NC=3)=NN2C=1C1=CC=CC(F)=C1 UHQWQCNMMZGHRC-UHFFFAOYSA-N 0.000 claims 1
- KMGQPMVTRBAPMV-UHFFFAOYSA-N n-[6-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-3-[4-fluoro-3-(morpholine-4-carbonyl)phenyl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CC(=O)NC=1N=C2C=CC(C=3C=C(NS(C)(=O)=O)C(Cl)=NC=3)=NN2C=1C(C=1)=CC=C(F)C=1C(=O)N1CCOCC1 KMGQPMVTRBAPMV-UHFFFAOYSA-N 0.000 claims 1
- ZHWOTURMYYTCTB-UHFFFAOYSA-N n-[6-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-3-iodoimidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound N=1N2C(I)=C(NC(=O)C)N=C2C=CC=1C1=CN=C(Cl)C(NS(C)(=O)=O)=C1 ZHWOTURMYYTCTB-UHFFFAOYSA-N 0.000 claims 1
- MQVPAFLDNHSDEI-UHFFFAOYSA-N n-[6-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-3-pyridin-4-ylimidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CC(=O)NC=1N=C2C=CC(C=3C=C(NS(C)(=O)=O)C(Cl)=NC=3)=NN2C=1C1=CC=NC=C1 MQVPAFLDNHSDEI-UHFFFAOYSA-N 0.000 claims 1
- XJUQIECUCFGNSA-UHFFFAOYSA-N n-[6-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C1=CN=C(Cl)C(NS(C)(=O)=O)=C1 XJUQIECUCFGNSA-UHFFFAOYSA-N 0.000 claims 1
- UCXPQJNZIRTUGH-UHFFFAOYSA-N n-[6-[6-chloro-5-(morpholin-4-ylsulfonylamino)pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)N1CCOCC1 UCXPQJNZIRTUGH-UHFFFAOYSA-N 0.000 claims 1
- HQMYZUNEFNTEQE-UHFFFAOYSA-N n-[6-[6-chloro-5-[(2-chloro-4-fluorophenyl)sulfonylamino]pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1Cl HQMYZUNEFNTEQE-UHFFFAOYSA-N 0.000 claims 1
- XUVGYKGUURQNNP-UHFFFAOYSA-N n-[6-[6-chloro-5-[(2-chloro-6-methylphenyl)sulfonylamino]pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=C(C)C=CC=C1Cl XUVGYKGUURQNNP-UHFFFAOYSA-N 0.000 claims 1
- SASGTCBMHBJCIK-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridazin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(N=NC=1Cl)=CC=1NS(=O)(=O)C1=CC=C(F)C=C1 SASGTCBMHBJCIK-UHFFFAOYSA-N 0.000 claims 1
- IDAXZUXBOFQTMN-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1-pyridin-2-ylbenzimidazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC2=CC=C(C=3C=C(NS(=O)(=O)C=4C=CC(F)=CC=4)C(Cl)=NC=3)C=C2N1C1=CC=CC=N1 IDAXZUXBOFQTMN-UHFFFAOYSA-N 0.000 claims 1
- VMOWYZQEUZXDFM-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1h-benzimidazol-2-yl]acetamide Chemical compound C=1C=C2NC(NC(=O)C)=NC2=CC=1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 VMOWYZQEUZXDFM-UHFFFAOYSA-N 0.000 claims 1
- WHKSVDCLCLYVSX-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-3-pyridin-4-ylimidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CC(=O)NC=1N=C2C=CC(C=3C=C(NS(=O)(=O)C=4C=CC(F)=CC=4)C(Cl)=NC=3)=NN2C=1C1=CC=NC=C1 WHKSVDCLCLYVSX-UHFFFAOYSA-N 0.000 claims 1
- XNIJHVMYDIVRJQ-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]imidazo[1,2-a]pyridin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2C=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 XNIJHVMYDIVRJQ-UHFFFAOYSA-N 0.000 claims 1
- FHOXICOTPQTJOQ-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 FHOXICOTPQTJOQ-UHFFFAOYSA-N 0.000 claims 1
- HYAVDBLWDKUYEK-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-methylphenyl)sulfonylamino]pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(C)C=C1 HYAVDBLWDKUYEK-UHFFFAOYSA-N 0.000 claims 1
- WVWKCLCEQFHKCY-UHFFFAOYSA-N n-[6-[6-chloro-5-[[3-(difluoromethoxy)phenyl]sulfonylamino]pyridin-3-yl]-3-(2-methylpyridin-4-yl)imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CC(=O)NC=1N=C2C=CC(C=3C=C(NS(=O)(=O)C=4C=C(OC(F)F)C=CC=4)C(Cl)=NC=3)=NN2C=1C1=CC=NC(C)=C1 WVWKCLCEQFHKCY-UHFFFAOYSA-N 0.000 claims 1
- HNFKWAKUAQTMRW-UHFFFAOYSA-N n-[6-[6-chloro-5-[[3-(difluoromethoxy)phenyl]sulfonylamino]pyridin-3-yl]-3-pyridin-3-ylimidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CC(=O)NC=1N=C2C=CC(C=3C=C(NS(=O)(=O)C=4C=C(OC(F)F)C=CC=4)C(Cl)=NC=3)=NN2C=1C1=CC=CN=C1 HNFKWAKUAQTMRW-UHFFFAOYSA-N 0.000 claims 1
- GTMAIZIZTDUMKQ-UHFFFAOYSA-N n-[6-[6-chloro-5-[[3-(difluoromethoxy)phenyl]sulfonylamino]pyridin-3-yl]-3-pyridin-4-ylimidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound CC(=O)NC=1N=C2C=CC(C=3C=C(NS(=O)(=O)C=4C=C(OC(F)F)C=CC=4)C(Cl)=NC=3)=NN2C=1C1=CC=NC=C1 GTMAIZIZTDUMKQ-UHFFFAOYSA-N 0.000 claims 1
- YHCSXAXEVJMGJD-UHFFFAOYSA-N n-[6-[6-chloro-5-[[3-(difluoromethoxy)phenyl]sulfonylamino]pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=CC(OC(F)F)=C1 YHCSXAXEVJMGJD-UHFFFAOYSA-N 0.000 claims 1
- MUWXXVHFJQHSBQ-UHFFFAOYSA-N n-[6-[6-chloro-5-[[4-(2-hydroxypropan-2-yl)phenyl]sulfonylamino]pyridin-3-yl]imidazo[1,2-b]pyridazin-2-yl]acetamide Chemical compound C1=CC2=NC(NC(=O)C)=CN2N=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(C(C)(C)O)C=C1 MUWXXVHFJQHSBQ-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 16
- 0 *C(**1[Al]C(*)***11)N1C1CCCCCC1 Chemical compound *C(**1[Al]C(*)***11)N1C1CCCCCC1 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical class 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- RSIHSWINMLWXQU-CSKARUKUSA-N FC(/C1=C/CCCCCCCC1)(F)F Chemical compound FC(/C1=C/CCCCCCCC1)(F)F RSIHSWINMLWXQU-CSKARUKUSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US843007P | 2007-12-19 | 2007-12-19 | |
| US61/008,430 | 2007-12-19 | ||
| PCT/US2008/013940 WO2009085230A1 (en) | 2007-12-19 | 2008-12-18 | Inhibitors of pi3 kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011507854A JP2011507854A (ja) | 2011-03-10 |
| JP2011507854A5 true JP2011507854A5 (enExample) | 2014-04-17 |
| JP5520831B2 JP5520831B2 (ja) | 2014-06-11 |
Family
ID=40364443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539504A Expired - Fee Related JP5520831B2 (ja) | 2007-12-19 | 2008-12-18 | Ｐｉ３キナーゼの阻害薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7820665B2 (enExample) |
| EP (1) | EP2231661A1 (enExample) |
| JP (1) | JP5520831B2 (enExample) |
| AR (1) | AR069862A1 (enExample) |
| AU (1) | AU2008343813B2 (enExample) |
| CA (1) | CA2710194C (enExample) |
| CL (1) | CL2008003798A1 (enExample) |
| PE (1) | PE20091268A1 (enExample) |
| TW (1) | TW200940544A (enExample) |
| WO (1) | WO2009085230A1 (enExample) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005080355A1 (en) * | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| WO2009018657A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| BRPI0815503A2 (pt) * | 2007-08-17 | 2014-09-30 | Icagen Inc | Composto, composição farmacêutica, e, métodos para modular a atividade de um canal de íon potássio em um indivíduo, para aumentar o fluxo de íon por meio de canais de potássio dependentes da voltagem em uma célula e para tratar, prevenir, inibir ou aliviar um distúrbio ou condição do sistema nervoso central ou periférico |
| CN103483251A (zh) | 2007-12-19 | 2014-01-01 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| EP2444403A1 (en) * | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
| AR071523A1 (es) * | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
| EP2307400B1 (en) * | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
| WO2010007099A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| JP2012521354A (ja) | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| WO2010132598A1 (en) * | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| JP5659224B2 (ja) | 2009-05-15 | 2015-01-28 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのアリールピリジン |
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| EP2558463A1 (en) * | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| WO2012058671A1 (en) | 2010-10-31 | 2012-05-03 | Endo Pharmaceuticals Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| EP2683243A4 (en) * | 2011-03-09 | 2014-12-03 | Celgene Avilomics Res Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| WO2012174312A2 (en) * | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Benzimidazole derivatives as antiviral agents |
| KR102030609B1 (ko) | 2011-09-02 | 2019-10-11 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| US10292390B2 (en) | 2011-11-04 | 2019-05-21 | Wisconsin Alumni Research Foundation | Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TWI574962B (zh) * | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| JP6267231B2 (ja) | 2012-12-21 | 2018-01-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール |
| CN104837844B (zh) | 2012-12-21 | 2017-08-29 | 百时美施贵宝公司 | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 |
| CN103965199B (zh) * | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| WO2014130470A1 (en) | 2013-02-19 | 2014-08-28 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
| BR112015018318A2 (pt) | 2013-02-21 | 2017-08-22 | Sunshine Lake Pharma Co Ltd | Composto, composição farmacêutica, uso de um composto ou de uma composição farmacêutica, e, métodos para prevenir, gerenciar, tratar ou diminuir a severidade de um distúrbio proliferativo em um paciente e para inibir ou modular a atividade de uma proteína quinase em uma amostra biológica |
| EP2970237B1 (en) | 2013-03-14 | 2017-09-27 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| US9650376B2 (en) | 2013-03-15 | 2017-05-16 | Knopp Biosciences Llc | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| MX391859B (es) | 2013-11-11 | 2025-03-12 | Amgen Inc | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| EP3094326A4 (en) | 2014-01-14 | 2017-07-26 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9493450B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2015134854A2 (en) * | 2014-03-06 | 2015-09-11 | Oyagen, Inc. | Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| ES2960991T3 (es) | 2014-09-12 | 2024-03-07 | Biohaven Therapeutics Ltd | Benzoimidazol-1,2-ilamidas como activadores del canal Kv7 |
| CN105503877A (zh) | 2014-09-24 | 2016-04-20 | 和记黄埔医药（上海）有限公司 | 咪唑并哒嗪类化合物及其用途 |
| CN104447756A (zh) * | 2014-11-10 | 2015-03-25 | 常州大学 | 一种五氟磺草胺中间体的制备方法 |
| CN104402890A (zh) * | 2014-11-10 | 2015-03-11 | 常州大学 | 一种制备五氟磺草胺的方法 |
| CN107531666A (zh) | 2015-02-20 | 2018-01-02 | 里格尔药品股份有限公司 | Gdf‑8抑制剂 |
| DK3831833T3 (da) | 2015-02-27 | 2022-11-14 | Incyte Holdings Corp | Fremgangsmåder til fremstillingen af en pi3k-inhibitor |
| PE20180455A1 (es) | 2015-04-03 | 2018-03-05 | Incyte Corp | Compuestos heterociclicos como inhibidores de lsd1 |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| CA2985542C (en) | 2015-05-20 | 2023-10-10 | Amgen Inc. | Triazole agonists of the apj receptor |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| AU2016315881B2 (en) * | 2015-09-03 | 2019-09-19 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| CN109414410B (zh) | 2016-04-22 | 2022-08-12 | 因赛特公司 | Lsd1抑制剂的制剂 |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| WO2018097944A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| WO2019018562A1 (en) | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| ES2905948T3 (es) * | 2017-10-30 | 2022-04-12 | Bristol Myers Squibb Co | Aminoimidazopiridazinas como inhibidores de cinasa |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| CN118955400A (zh) | 2018-03-19 | 2024-11-15 | 诺普生物科学有限责任公司 | Kv7通道激活剂组合物和使用方法 |
| MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
| MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| CN119258070A (zh) | 2018-06-01 | 2025-01-07 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
| MA51848A (fr) | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| CN113166153B (zh) | 2018-07-05 | 2024-11-01 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| BR112021003839A2 (pt) | 2018-08-31 | 2021-07-27 | Amgen Inc. | processos para preparar um inibidor mdm2 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| KR102892275B1 (ko) * | 2019-02-22 | 2025-11-27 | 주식회사 퍼스트바이오테라퓨틱스 | 이미다조피리디닐 화합물 및 신경퇴행성 장애의 치료를 위한 그의 용도 |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
| MX2022001940A (es) | 2019-08-14 | 2022-05-10 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. |
| CN119930610A (zh) | 2019-10-11 | 2025-05-06 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| EP4045047A1 (en) | 2019-10-15 | 2022-08-24 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
| CN112047950B (zh) * | 2020-09-14 | 2023-07-25 | 华东师范大学 | 咪唑并吡嗪类衍生物及其合成方法和应用 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN120887867A (zh) * | 2025-07-10 | 2025-11-04 | 浙江中医药大学 | 一类新型喹啉联芳杂环pi3k/hdac双靶点小分子抑制剂及其应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH505543A (de) * | 1968-11-01 | 1971-04-15 | Ciba Geigy Ag | Schädlingsbekämpfungsmittel |
| AUPP873799A0 (en) * | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
| JP2003521543A (ja) * | 2000-02-07 | 2003-07-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用 |
| CN100345830C (zh) * | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
| US7449488B2 (en) * | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| AU2003255528B2 (en) | 2002-07-10 | 2009-07-16 | Merck Serono Sa | Azolidinone-vinyl fused-benzene derivatives |
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| AR042956A1 (es) * | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| WO2004098494A2 (en) | 2003-04-30 | 2004-11-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| GB0315203D0 (en) | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| WO2005080380A1 (en) * | 2004-02-03 | 2005-09-01 | Eli Lilly And Company | Kinase inhibitors |
| WO2005076854A2 (en) * | 2004-02-04 | 2005-08-25 | Smithkline Beecham Corporation | Pyrimidinone compounds useful as kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN101056633A (zh) | 2004-10-12 | 2007-10-17 | 应用研究系统Ars股份公司 | 用于贫血治疗的PI3激酶γ抑制剂 |
| HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| EP1812440B1 (en) * | 2004-11-04 | 2010-09-22 | Vertex Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| ES2274712B1 (es) * | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| WO2007129052A1 (en) | 2006-05-03 | 2007-11-15 | Astrazeneca Ab | Pyrazole derivatives and their use as pi3k inhibitors |
| WO2007129044A1 (en) | 2006-05-03 | 2007-11-15 | Astrazeneca Ab | Thiazole derivatives and their use as anti-tumour agents |
| GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
| EP2029593A1 (en) * | 2006-05-22 | 2009-03-04 | AstraZeneca AB | Indole derivatives |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| AU2007278178A1 (en) | 2006-07-28 | 2008-01-31 | Novartis Ag | 2,4-substituted quinazolines as lipid kinase inhibitors |
| EP2058309A4 (en) * | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| SG174086A1 (en) * | 2006-08-30 | 2011-09-29 | Cellzome Ltd | Triazole derivatives as kinase inhibitors |
| RU2009115954A (ru) | 2006-09-29 | 2010-11-10 | Новартис АГ (CH) | Пиразолопиримидины в качестве ингибиторов липидной киназы р13к |
| RU2009120388A (ru) | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Имидазопиридазины в качестве ингибиторов липидкиназы |
| AR064154A1 (es) | 2006-12-07 | 2009-03-18 | Piramed Ltd | Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas |
| PE20081679A1 (es) | 2006-12-07 | 2008-12-18 | Hoffmann La Roche | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso |
| JP5508027B2 (ja) | 2007-02-22 | 2014-05-28 | メルク セローノ ソシエテ アノニム | キノキサリン化合物及びその使用 |
| US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| KR20100019489A (ko) | 2007-05-09 | 2010-02-18 | 노파르티스 아게 | Ｐｉ３ｋ 지질 키나제 억제제로서의 치환된 이미다조피리다진 |
| US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| US8131310B2 (en) | 2007-05-18 | 2012-03-06 | Research In Motion Limited | Method and system for discontinuous reception de-synchronization detection |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| WO2008152387A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Quinazoline derivatives as pi3 kinase inhibitors |
| EP2158207B1 (en) | 2007-06-12 | 2011-05-25 | F. Hoffmann-La Roche AG | Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| WO2008152394A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
| UY31137A1 (es) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| EP2170884A2 (en) | 2007-06-25 | 2010-04-07 | Boehringer Ingelheim International GmbH | Chemical compounds |
| JP2010533173A (ja) | 2007-07-11 | 2010-10-21 | オークランド・ユニサーヴィシズ・リミテッド | ピラゾロ［１，５−ａ］ピリジン、及び癌治療におけるその使用 |
| KR20100049073A (ko) * | 2007-07-18 | 2010-05-11 | 노파르티스 아게 | 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도 |
| ES2401557T3 (es) | 2007-08-02 | 2013-04-22 | Amgen, Inc | Moduladores de Pl3 cinasas y métodos de uso |
| CN101883774A (zh) | 2007-10-16 | 2010-11-10 | 惠氏有限责任公司 | 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途 |
| EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
| GB0721095D0 (en) | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
| ES2537624T3 (es) | 2007-10-26 | 2015-06-10 | F. Hoffmann-La Roche Ag | Derivados purina útiles como inhibidores de la quinasa PI3 |
| SG186040A1 (en) | 2007-11-27 | 2012-12-28 | Cellzome Ltd | Amino triazoles as pi3k inhibitors |
| WO2009070524A1 (en) | 2007-11-27 | 2009-06-04 | Wyeth | Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors |
| US8399483B2 (en) | 2007-12-21 | 2013-03-19 | Ucb Pharma S.A. | Quinoxaline and quinoline derivatives as kinase inhibitors |
| CN102014914A (zh) | 2008-01-15 | 2011-04-13 | 惠氏有限责任公司 | 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成 |
| ES2494365T3 (es) | 2008-01-30 | 2014-09-15 | Genentech, Inc. | Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso |
| US20090192176A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
-
2008
- 2008-12-18 CL CL2008003798A patent/CL2008003798A1/es unknown
- 2008-12-18 CA CA2710194A patent/CA2710194C/en not_active Expired - Fee Related
- 2008-12-18 WO PCT/US2008/013940 patent/WO2009085230A1/en not_active Ceased
- 2008-12-18 AU AU2008343813A patent/AU2008343813B2/en not_active Ceased
- 2008-12-18 JP JP2010539504A patent/JP5520831B2/ja not_active Expired - Fee Related
- 2008-12-18 US US12/317,166 patent/US7820665B2/en active Active
- 2008-12-18 EP EP08867948A patent/EP2231661A1/en not_active Withdrawn
- 2008-12-18 PE PE2008002118A patent/PE20091268A1/es not_active Application Discontinuation
- 2008-12-19 AR ARP080105607A patent/AR069862A1/es not_active Application Discontinuation
- 2008-12-19 TW TW097149904A patent/TW200940544A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507854A5 (enExample) | ||
| AU2019283921B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| CN108699057B (zh) | 5-取代的2-(吗啉-4-基)-1,7-萘啶 | |
| JP5865519B2 (ja) | イミダゾピロリジノン化合物 | |
| KR101799126B1 (ko) | 키나아제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 | |
| AU2015369983B2 (en) | Thieno[2,3-c]pyrrol-4-one derivatives as ERK inhibitors | |
| ES2354716T3 (es) | Compuestos de imidazo[1,2-a]piridina como inhibidores de vegf-r2. | |
| AU2019340767B2 (en) | Triazolo-pyrimidine compounds and uses thereof | |
| CA2780190C (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP2024502886A (ja) | がんを処置及び／又は予防するためのｓｏｓ１阻害薬の医薬組合せ | |
| US10023576B2 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | |
| HRP20240994T1 (hr) | Spoj inhibitora jak i njegova uporaba | |
| AU2015276264B2 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| CN102388055B (zh) | 咪唑并[2,1-b][1,3,4]噻二唑衍生物 | |
| JP2012512887A5 (enExample) | ||
| HRP20151398T1 (hr) | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze | |
| RU2018104702A (ru) | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ | |
| CN101605787A (zh) | 调节c-fms和/或c-kit活性的化合物及其应用 | |
| JP2016538316A5 (enExample) | ||
| RU2015139590A (ru) | ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ | |
| AU2009259867A1 (en) | Triazolopyridine JAK inhibitor compounds and methods | |
| JP2016537384A5 (enExample) | ||
| CN105283454A (zh) | 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉 | |
| JP2016537384A (ja) | ピロロピロロン誘導体およびｂｅｔ阻害剤としてのその使用 | |
| KR20150068956A (ko) | 세린/트레오닌 키나아제 억제제 |